Prediction of preeclampsia by placental protein 13 and background risk factors and its prevention by aspirin

References

[1] Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn. 2011;31:66–74.10.1002/pd.2660Search in Google Scholar PubMed

[2] Balogh A, Pozsgay J, Matko J, Dong Z, Kim CJ, Varkonyi T, et al. Placental protein 13 (PP13/galectin-13) undergoes lipid raft-associated subcellular redistribution in the syncytiotrophoblast in preterm preeclampsia and HELLP syndrome. Am J Obstet Gynecol. 2011;205:156 e1–14.10.1016/j.ajog.2011.03.023Search in Google Scholar PubMed PubMed Central

[3] Bar J. The treatment approach for hypertension in pregnancy. Israel. Society of Obstetrics Gynecology. 18.03.2009. http://www.obgyn.org.il/niarEmda_info.asp?info_id=56381.Search in Google Scholar

[4] Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol. 2010;116:402–14.10.1097/AOG.0b013e3181e9322aSearch in Google Scholar PubMed

[5] Calhoun KC, Barnhart KT, Elovitz MA, Srinivas SK. Evaluating the Association between Assisted Conception and the Severity of Preeclampsia. ISRN Obstet Gynecol. 2011;2011:928592.10.5402/2011/928592Search in Google Scholar PubMed PubMed Central

[6] Cetin I, Huppertz B, Burton G, Cuckle H, Gonen R, Lapaire O, et al. Pregenesys pre-eclampsia markers consensus meeting: what do we require from markers, risk assessment and model systems to tailor preventive strategies? Placenta. 2011;32: S4–16.10.1016/j.placenta.2010.11.022Search in Google Scholar PubMed

[7] Cuckle HS. Screening for pre-eclampsia – lessons from aneuploidy screening. Placenta. 2011;32:S42–8.10.1016/j.placenta.2010.07.015Search in Google Scholar PubMed

[8] Gebhardt S, Bruiners N, Hillermann R. A novel exonic variant (221delT) in the LGALS13 gene encoding placental protein 13 (PP13) is associated with preterm labour in a low risk population. J Reprod Immunol. 2009;82:166–73.10.1016/j.jri.2009.07.004Search in Google Scholar PubMed

[9] Giguere Y, Charland M, Bujold E, Bernard N, Grenier S, Rousseau F, et al. Combining biochemical and ultrasonographic markers in predicting preeclampsia: a systematic review. Clin Chem. 2010;56:361–75.10.1373/clinchem.2009.134080Search in Google Scholar PubMed

[10] Gizurarson S, Huppertz B, Osol G, Skarphedinsson JO, Mandala M, Meiri H. Effects of placental protein 13 on the cardiovascular system in gravid and non-gravid rodents. Fetal Diagn Ther. 2013;33:257–64.10.1159/000345964Search in Google Scholar PubMed

[11] Gonen R, Shahar R, Grimpel YI, Chefetz I, Sammar M, Meiri H, et al. Placental protein 13 as an early marker for pre-eclampsia: a prospective longitudinal study. BJOG. 2008;115:1465–72.10.1111/j.1471-0528.2008.01902.xSearch in Google Scholar PubMed

[12] Grimpel YI, Kivity V, Cohen A, Meiri H, Sammar M, Gonen R, et al. Effects of calcium, magnesium, low-dose aspirin and low-molecular-weight heparin on the release of PP13 from placental explants. Placenta. 2011;32 Suppl:S55–64.10.1016/j.placenta.2010.11.019Search in Google Scholar PubMed

[13] Gynecologists ACoOa. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Int J Gynaecol Obstet. 2002;77:67–75.Search in Google Scholar

[14] Huppertz B. Placental origins of preeclampsia: challenging the current hypothesis. Hypertension. 2008;51:970–5.10.1161/HYPERTENSIONAHA.107.107607Search in Google Scholar PubMed

[15] Huppertz B, Meiri H, Gizurarson S, Osol G, Sammar M. Placental protein 13 (PP13): a new biological target shifting individualized risk assessment to personalized drug design combating pre-eclampsia. Hum Reprod Update. 2013;19: 391–405.10.1093/humupd/dmt003Search in Google Scholar PubMed

[16] Khalil A, Cowans NJ, Spencer K, Goichman S, Meiri H, Harrington K. First-trimester markers for the prediction of pre-eclampsia in women with a-priori high risk. Ultrasound Obstet Gynecol. 2010;35:671–9.10.1002/uog.7559Search in Google Scholar PubMed

[17] Lindheimer MD, Taler SJ, Cunningham FG. ASH position paper: hypertension in pregnancy. J Clin Hypertens (Greenwich). 2009;11:214–25.10.1111/j.1751-7176.2009.00085.xSearch in Google Scholar PubMed PubMed Central

[18] Melchiorre K, Thilaganathan B. Maternal cardiac function in preeclampsia. Curr Opin Obstet Gynecol. 2011;23:440–719.10.1097/GCO.0b013e32834cb7a4Search in Google Scholar PubMed

[19] NICE. Hypertension in pregnancy: the management of hypertensive disorders during pregnancy. 2010.Search in Google Scholar

[20] Nicolaides KH, Bindra R, Turan OM, Chefetz I, Sammar M, Meiri H, et al. A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound. Ultrasound Obstet Gynecol. 2006;27:13–7.10.1002/uog.2686Search in Google Scholar PubMed

[21] Onwudiwe N, Yu CK, Poon LC, Spiliopoulos I, Nicolaides KH. Prediction of pre-eclampsia by a combination of maternal history, uterine artery Doppler and mean arterial pressure. Ultrasound Obstet Gynecol. 2008;32:877–83.10.1002/uog.6124Search in Google Scholar PubMed

[22] Orendi K, Gauster M, Moser G, Meiri H, Huppertz B. Effects of vitamins C and E, acetylsalicylic acid and heparin on fusion, beta-hCG and PP13 expression in BeWo cells. Placenta. 2010;31:431–8.10.1016/j.placenta.2010.02.017Search in Google Scholar PubMed

[23] Pijnenborg R, Vercruysse L, Hanssens M. Fetal-maternal conflict, trophoblast invasion, preeclampsia, and the red queen. Hypertens Pregnancy. 2008;27:183–96.10.1080/10641950701826711Search in Google Scholar PubMed

[24] Poon LC, Akolekar R, Lachmann R, Beta J, Nicolaides KH. Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11-13 weeks. Ultrasound Obstet Gynecol. 2010;35:662–70.10.1002/uog.7628Search in Google Scholar

[25] Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005;308:1592–4.10.1126/science.1111726Search in Google Scholar

[26] Roberts JM, Cooper DW. Pathogenesis and genetics of pre-eclampsia. Lancet. 2001;357:53–6.10.1016/S0140-6736(00)03577-7Search in Google Scholar

[27] Sammar M, Nisemblat S, Fleischfarb Z, Golan A, Sadan O, Meiri H, et al. Placenta-bound and body fluid PP13 and its mRNA in normal pregnancy compared to preeclampsia, HELLP and preterm delivery. Placenta. 2011;32 Suppl:S30–6.10.1016/j.placenta.2010.09.006Search in Google Scholar

[28] Shmueli A, Meiri H, Gonen R. Economic assessment of screening for pre-eclampsia. Prenat Diagn. 2012;32:29–38.10.1002/pd.2871Search in Google Scholar

[29] Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365:785–99.10.1016/S0140-6736(05)17987-2Search in Google Scholar

[30] Svirsky R, Meiri H, Herzog A, Kivity V, Cuckle H, Maymon R. First trimester maternal serum placental protein 13 levels in singleton vs. twin pregnancies with and without severe pre-eclampsia. J Perinat Med. 2013;41:561–6.Search in Google Scholar

[31] Than NG, Romero R, Goodman M, Weckle A, Xing J, Dong Z, et al. A primate subfamily of galectins expressed at the maternal-fetal interface that promote immune cell death. Proc Natl Acad Sci USA. 2009;106:9731–6.10.1073/pnas.0903568106Search in Google Scholar PubMed PubMed Central

[32] Than NG, Romero R, Meiri H, Erez O, Xu Y, Tarquini F, et al. PP13, maternal ABO blood groups and the risk assessment of pregnancy complications. PLoS One. 2011;6:e21564.10.1371/journal.pone.0021564Search in Google Scholar PubMed PubMed Central

[33] Valapala M, Vishwanatha JK. Lipid raft endocytosis and exosomal transport facilitate extracellular trafficking of annexin A2. J Biol Chem. 2011;286:30911–25.10.1074/jbc.M111.271155Search in Google Scholar PubMed PubMed Central

[34] WHO. Make every mother and child count. Geneva, Switzerland: World Health Organization, 2005.Search in Google Scholar

[35] Wortelboer EJ, Koster MP, Cuckle HS, Stoutenbeek PH, Schielen PC, Visser GH. First-trimester placental protein 13 and placental growth factor: markers for identification of women destined to develop early-onset pre-eclampsia. BJOG. 2010;117:1384–9.10.1111/j.1471-0528.2010.02690.xSearch in Google Scholar PubMed

[36] Wright D, Akolekar R, Syngelaki A, Poon LC, Nicolaides KH. A competing risks model in early screening for preeclampsia. Fetal Diagn Ther. 2012;32:171–8.10.1159/000338470Search in Google Scholar PubMed